Andrew Buesking
Senior Director, Chemistry Prelude Therapeutics
Seminars
Wednesday 28th October 2026
Identification of First-in-Class KAT6A Degraders Leading to Potent & KAT6A-Selective Oral Development Candidate PRT13722
5:00 pm
- Discovery of KAT6A degrader compounds
- Characterization and proof-of-concept studies with KAT6A degraders
- Preclinical profile of KAT6A-selective development candidate PRT13722
